Bhagwat K. Gunale
Pune, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Proceedings of the second annual dengue endgame summit: A call to action.
Journal: PLoS neglected tropical diseases
Published: April 28, 2025
Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
Journal: Lancet (London, England)
Published: January 02, 2025
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Journal: Human vaccines & immunotherapeutics
Published: March 21, 2024
Proceedings of the dengue endgame summit: Imagining a world with dengue control.
Journal: Vaccine
Published: November 20, 2023
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
Journal: The Lancet. Infectious diseases
Published: October 04, 2023
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Journal: JAMA pediatrics
Published: July 31, 2023
Post-marketing safety surveillance of the rotavirus vaccine in India.
Journal: Vaccine: X
Published: April 27, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Journal: Scientific reports
Published: February 10, 2023
A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
Journal: Vaccine
Published: January 31, 2023
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure.
Journal: The Lancet regional health. Southeast Asia
Published: January 30, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.
Journal: The Lancet regional health. Southeast Asia
Published: August 10, 2022
Last Updated: 09/26/2026